DM199 (rinvecalinase alfa)
Preeclampsia (PE)
Key Facts
About DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious ischemic disorders, with a mission to improve patient outcomes by targeting the underlying vascular injury. Its strategy is centered on DM199, a recombinant form of the human tissue kallikrein-1 protein, which aims to restore vascular function through a multi-faceted mechanism. The company has achieved key milestones, including positive interim Phase 2 data in preeclampsia and the advancement of a Phase 2/3 study in acute ischemic stroke, positioning it to address multi-billion dollar markets with no approved disease-modifying treatments.
View full company profileAbout DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious ischemic disorders, with a mission to improve patient outcomes by targeting the underlying vascular injury. Its strategy is centered on DM199, a recombinant form of the human tissue kallikrein-1 protein, which aims to restore vascular function through a multi-faceted mechanism. The company has achieved key milestones, including positive interim Phase 2 data in preeclampsia and the advancement of a Phase 2/3 study in acute ischemic stroke, positioning it to address multi-billion dollar markets with no approved disease-modifying treatments.
View full company profileAbout DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious ischemic disorders, with a mission to improve patient outcomes by targeting the underlying vascular injury. Its strategy is centered on DM199, a recombinant form of the human tissue kallikrein-1 protein, which aims to restore vascular function through a multi-faceted mechanism. The company has achieved key milestones, including positive interim Phase 2 data in preeclampsia and the advancement of a Phase 2/3 study in acute ischemic stroke, positioning it to address multi-billion dollar markets with no approved disease-modifying treatments.
View full company profile